These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 32641239)

  • 1. Bowel resection or repair at the time of cytoreductive surgery for ovarian malignancy is associated with increased complication rate: An ACS-NSQIP study.
    Bernard L; Boucher J; Helpman L
    Gynecol Oncol; 2020 Sep; 158(3):597-602. PubMed ID: 32641239
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection.
    Chalif J; Chambers LM; Yao M; Kuznicki M; DeBernardo R; Rose PG; Michener CM; Vargas R
    Gynecol Oncol; 2024 Jul; 186():161-169. PubMed ID: 38691986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive validity of American College of Surgeons: National Surgical Quality Improvement Project risk calculator in patients with ovarian cancer undergoing interval debulking surgery.
    Manning-Geist B; Cathcart AM; Sullivan MW; Pelletier A; Cham S; Muto MG; Del Carmen M; Growdon WB; Sisodia RC; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2021 Oct; 31(10):1356-1362. PubMed ID: 34518239
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and outcomes after bowel surgery and ostomy formation at the time of debulking surgery for advanced-stage epithelial ovarian carcinoma.
    Gockley AA; Fiascone S; Hicks Courant K; Pepin K; Del Carmen M; Clark RM; Goldberg J; Horowitz N; Berkowitz R; Worley M
    Int J Gynecol Cancer; 2019 Mar; 29(3):585-592. PubMed ID: 30833444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appendectomy at the time of ovarian cancer staging increases infectious complications: a National Surgical Quality Improvement Program (NSQIP) propensity score-stratified analysis.
    Bernard L; Chen I; Le T
    Int J Gynecol Cancer; 2020 Oct; 30(10):1542-1547. PubMed ID: 32848024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using evidence to direct quality improvement efforts: Defining the highest impact complications after complex cytoreductive surgery for ovarian cancer.
    Narasimhulu DM; Bews KA; Hanson KT; Chang YH; Dowdy SC; Cliby WA
    Gynecol Oncol; 2020 Feb; 156(2):278-283. PubMed ID: 31785863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. National trends in bowel and upper abdominal procedures in ovarian cancer surgery.
    Dottino JA; He W; Sun CC; Zhao H; Fu S; Rauh-Hain JA; Suidan RS; Lu KH; Giordano SH; Meyer LA
    Int J Gynecol Cancer; 2020 Aug; 30(8):1195-1202. PubMed ID: 32616627
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of bowel surgery with cytoreduction for epithelial ovarian cancer.
    Cai HB; Zhou YF; Chen HZ; Hou HY
    Clin Oncol (R Coll Radiol); 2007 Dec; 19(10):757-62. PubMed ID: 17889517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unanticipated 30-day readmission following rectosigmoid resection at the time of cytoreductive surgery in patients with advanced stage ovarian cancer.
    Sanders BE; Saharti S; Laus K; Bristow RE; Eskander RN
    J Obstet Gynaecol; 2021 Aug; 41(6):956-961. PubMed ID: 33228421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bowel Resection Outcomes in Ovarian Cancer Cytoreductive Surgery by Surgeon Specialty.
    Ebott J; Has P; Raker C; Robison K
    JAMA Surg; 2024 Oct; 159(10):1188-1194. PubMed ID: 39110445
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does timing of intraperitoneal chemotherapy initiation following primary cytoreductive surgery with bowel resection impact outcomes in patients with advanced ovarian cancer?
    Nica A; Covens A; Parra-Herran C; May T
    Gynecol Oncol; 2020 Sep; 158(3):622-630. PubMed ID: 32561124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive and Prognostic Implication of Bowel Resections During Primary Cytoreductive Surgery in Advanced Epithelial Ovarian Cancer.
    Bartl T; Schwameis R; Stift A; Bachleitner-Hofmann T; Reinthaller A; Grimm C; Polterauer S
    Int J Gynecol Cancer; 2018 Nov; 28(9):1664-1671. PubMed ID: 30371563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanical and oral antibiotic bowel preparation in ovarian cancer debulking: Are we lowering or just trading surgical complications?
    Wang CC; Al-Rubaye R; Tran V; Montemorano L; Al-Niaimi A
    Gynecol Oncol; 2022 Jul; 166(1):76-84. PubMed ID: 35589434
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perioperative outcomes of extensive bowel resection during cytoreductive surgery in patients with advanced ovarian cancer.
    Son JH; Kong TW; Paek J; Chang SJ; Ryu HS
    J Surg Oncol; 2019 Jun; 119(7):1011-1015. PubMed ID: 30737795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Morbidity of rectosigmoid resection and primary anastomosis in patients undergoing primary cytoreductive surgery for advanced epithelial ovarian cancer.
    Mourton SM; Temple LK; Abu-Rustum NR; Gemignani ML; Sonoda Y; Bochner BH; Barakat RR; Chi DS
    Gynecol Oncol; 2005 Dec; 99(3):608-14. PubMed ID: 16153697
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Postoperative complications in women with ovarian cancer stratified by cytoreductive surgery outcome.
    Polan RM; Slota JM; Barber EL
    J Surg Oncol; 2023 Oct; 128(5):891-901. PubMed ID: 37382209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ARIA II: a randomized controlled trial of near-infrared Angiography during RectosIgmoid resection and Anastomosis in women with ovarian cancer.
    Leitao MM; Iasonos A; Tomberlin M; Moukarzel LA; Price H; Bennetti G; Ramesh B; Chi DS; Long Roche K; Sonoda Y; Al-Niami A; Mueller JJ; Gardner GJ; Broach V; Jewell EL; Kim S; Feinberg J; Abu-Rustum NR; Zivanovic O
    Int J Gynecol Cancer; 2024 Jul; 34(7):1098-1101. PubMed ID: 38514101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Abdominoperineal Resection, Pelvic Exenteration, and Additional Organ Resection Increase the Risk of Surgical Site Infection after Elective Colorectal Surgery: An American College of Surgeons National Surgical Quality Improvement Program Analysis.
    Kwaan MR; Melton GB; Madoff RD; Chipman JG
    Surg Infect (Larchmt); 2015 Dec; 16(6):675-83. PubMed ID: 26237302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes Associated With a Five-Point Surgical Site Infection Prevention Bundle in Women Undergoing Surgery for Ovarian Cancer.
    Lippitt MH; Fairbairn MG; Matsuno R; Stone RL; Tanner EJ; Wick EC; Angarita AC; Roche KL; Levinson KL; Bergstrom JE; Sinno AK; Curless MS; Wethington S; Temkin SM; Efron J; Hobson D; Fader AN
    Obstet Gynecol; 2017 Oct; 130(4):756-764. PubMed ID: 28885412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morbidity of rectosigmoid resection in cytoreductive surgery for ovarian cancer. Risk factor analysis.
    Fournier M; Huchon C; Ngo C; Bensaid C; Bats AS; Combe P; le FrèreBelda MA; Fournier L; Berger A; Lecuru F
    Eur J Surg Oncol; 2018 Jun; 44(6):750-753. PubMed ID: 29580734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.